Kenneth D. Mandl, MD, MPH; Florence T. Bourgeois, MD, MPH
JAMA. 2017;318(19):1859-1860. doi:10.1001/jama.2017.15028
This Viewpoint discusses how a clinical information commons, a health care system鈥檚 database of all its patient-based data, could make genetically based clinical diagnoses more scientific and potentially improve patient outcomes.
Peter B. Bach, MD; Sergio A. Giralt, MD; Leonard B. Saltz, MD
JAMA. 2017;318(19):1861-1862. doi:10.1001/jama.2017.15218
This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.
Ezekiel J. Emanuel, MD, PhD; Aaron Glickman, BA; David Johnson, MPP
free access
JAMA. 2017;318(19):1863-1864. doi:10.1001/jama.2017.15686
This Viewpoint proposes a new Affordability Index measure, the ratio of the mean cost of an employer-sponsored family health insurance policy divided by median household income, to describe US families鈥 ability to pay for health care.
Alexander Billioux, MD, DPhil; Patrick H. Conway, MD, MSc; Dawn E. Alley, PhD
JAMA. 2017;318(19):1865-1866. doi:10.1001/jama.2017.15063
This Viewpoint discusses the Centers for Medicare & Medicaid Services鈥 Accountable Health Communities project to test the role of community integrators鈥攐rganizations within a community that can represent its needs and engage stakeholders to work toward improvements in health鈥攁s a possible mechanism to decrease life expectancy disparities across the United States.